These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Non-invasive prediction of IDH-wildtype genotype in gliomas using dynamic Vettermann F; Suchorska B; Unterrainer M; Nelwan D; Forbrig R; Ruf V; Wenter V; Kreth FW; Herms J; Bartenstein P; Tonn JC; Albert NL Eur J Nucl Med Mol Imaging; 2019 Nov; 46(12):2581-2589. PubMed ID: 31410540 [TBL] [Abstract][Full Text] [Related]
6. Role of O-(2-18F-fluoroethyl)-L-tyrosine PET as a diagnostic tool for detection of malignant progression in patients with low-grade glioma. Galldiks N; Stoffels G; Ruge MI; Rapp M; Sabel M; Reifenberger G; Erdem Z; Shah NJ; Fink GR; Coenen HH; Langen KJ J Nucl Med; 2013 Dec; 54(12):2046-54. PubMed ID: 24159047 [TBL] [Abstract][Full Text] [Related]
7. Diagnostic performance of 18F-FET PET in newly diagnosed cerebral lesions suggestive of glioma. Rapp M; Heinzel A; Galldiks N; Stoffels G; Felsberg J; Ewelt C; Sabel M; Steiger HJ; Reifenberger G; Beez T; Coenen HH; Floeth FW; Langen KJ J Nucl Med; 2013 Feb; 54(2):229-35. PubMed ID: 23232275 [TBL] [Abstract][Full Text] [Related]
8. Comparison of 3'-deoxy-3'-[18F]fluorothymidine PET and O-(2-[18F]fluoroethyl)-L-tyrosine PET in patients with newly diagnosed glioma. Jeong SY; Lim SM Nucl Med Biol; 2012 Oct; 39(7):977-81. PubMed ID: 22483845 [TBL] [Abstract][Full Text] [Related]
9. Comparison of Unterrainer M; Fleischmann DF; Diekmann C; Vomacka L; Lindner S; Vettermann F; Brendel M; Wenter V; Ertl-Wagner B; Herms J; Wetzel C; Rupprecht R; Tonn JC; Belka C; Bartenstein P; Niyazi M; Albert NL Eur J Nucl Med Mol Imaging; 2019 Mar; 46(3):580-590. PubMed ID: 30244386 [TBL] [Abstract][Full Text] [Related]
10. Correlation of (18)F-fluoroethyl tyrosine positron-emission tomography uptake values and histomorphological findings by stereotactic serial biopsy in newly diagnosed brain tumors using a refined software tool. Lopez WO; Cordeiro JG; Albicker U; Doostkam S; Nikkhah G; Kirch RD; Trippel M; Reithmeier T Onco Targets Ther; 2015; 8():3803-15. PubMed ID: 26719708 [TBL] [Abstract][Full Text] [Related]
11. FET PET for the evaluation of untreated gliomas: correlation of FET uptake and uptake kinetics with tumour grading. Pöpperl G; Kreth FW; Mehrkens JH; Herms J; Seelos K; Koch W; Gildehaus FJ; Kretzschmar HA; Tonn JC; Tatsch K Eur J Nucl Med Mol Imaging; 2007 Dec; 34(12):1933-42. PubMed ID: 17763848 [TBL] [Abstract][Full Text] [Related]
12. Prognostic Value of O-(2-[18F]-Fluoroethyl)-L-Tyrosine-Positron Emission Tomography Imaging for Histopathologic Characteristics and Progression-Free Survival in Patients with Low-Grade Glioma. Bette S; Gempt J; Delbridge C; Kirschke JS; Schlegel J; Foerster S; Huber T; Pyka T; Zimmer C; Meyer B; Ringel F World Neurosurg; 2016 May; 89():230-9. PubMed ID: 26855307 [TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of dynamic 18F-FET PET in newly diagnosed astrocytic high-grade glioma. Jansen NL; Suchorska B; Wenter V; Schmid-Tannwald C; Todica A; Eigenbrod S; Niyazi M; Tonn JC; Bartenstein P; Kreth FW; la Fougère C J Nucl Med; 2015 Jan; 56(1):9-15. PubMed ID: 25537990 [TBL] [Abstract][Full Text] [Related]
14. Early static (18)F-FET-PET scans have a higher accuracy for glioma grading than the standard 20-40 min scans. Albert NL; Winkelmann I; Suchorska B; Wenter V; Schmid-Tannwald C; Mille E; Todica A; Brendel M; Tonn JC; Bartenstein P; la Fougère C Eur J Nucl Med Mol Imaging; 2016 Jun; 43(6):1105-14. PubMed ID: 26666239 [TBL] [Abstract][Full Text] [Related]
15. Prediction of oligodendroglial histology and LOH 1p/19q using dynamic [(18)F]FET-PET imaging in intracranial WHO grade II and III gliomas. Jansen NL; Schwartz C; Graute V; Eigenbrod S; Lutz J; Egensperger R; Pöpperl G; Kretzschmar HA; Cumming P; Bartenstein P; Tonn JC; Kreth FW; la Fougère C; Thon N Neuro Oncol; 2012 Dec; 14(12):1473-80. PubMed ID: 23090986 [TBL] [Abstract][Full Text] [Related]
16. Prediction of survival in patients with IDH-wildtype astrocytic gliomas using dynamic O-(2-[ Bauer EK; Stoffels G; Blau T; Reifenberger G; Felsberg J; Werner JM; Lohmann P; Rosen J; Ceccon G; Tscherpel C; Rapp M; Sabel M; Filss CP; Shah NJ; Neumaier B; Fink GR; Langen KJ; Galldiks N Eur J Nucl Med Mol Imaging; 2020 Jun; 47(6):1486-1495. PubMed ID: 32034446 [TBL] [Abstract][Full Text] [Related]
17. Dynamic O-(2-[18F]fluoroethyl)-L-tyrosine (F-18 FET) PET for glioma grading: assessment of individual probability of malignancy. Calcagni ML; Galli G; Giordano A; Taralli S; Anile C; Niesen A; Baum RP Clin Nucl Med; 2011 Oct; 36(10):841-7. PubMed ID: 21892031 [TBL] [Abstract][Full Text] [Related]
18. Dynamic 18F-FET PET in newly diagnosed astrocytic low-grade glioma identifies high-risk patients. Jansen NL; Suchorska B; Wenter V; Eigenbrod S; Schmid-Tannwald C; Zwergal A; Niyazi M; Drexler M; Bartenstein P; Schnell O; Tonn JC; Thon N; Kreth FW; la Fougère C J Nucl Med; 2014 Feb; 55(2):198-203. PubMed ID: 24379223 [TBL] [Abstract][Full Text] [Related]
19. Analysis of 18F-FET PET for grading of recurrent gliomas: is evaluation of uptake kinetics superior to standard methods? Pöpperl G; Kreth FW; Herms J; Koch W; Mehrkens JH; Gildehaus FJ; Kretzschmar HA; Tonn JC; Tatsch K J Nucl Med; 2006 Mar; 47(3):393-403. PubMed ID: 16513607 [TBL] [Abstract][Full Text] [Related]
20. Prognostic Value of O-(2-[ Kertels O; Kessler AF; Mihovilovic MI; Stolzenburg A; Linsenmann T; Samnick S; Brändlein S; Monoranu CM; Ernestus RI; Buck AK; Löhr M; Lapa C Mol Imaging Biol; 2019 Dec; 21(6):1174-1181. PubMed ID: 30977078 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]